Maravai Lifesciences Soars Following $17 Takeover Bid from Thomas H. Lee
June 19, 2023
🌥️Trending News
Maravai Lifesciences ($NASDAQ:MRVI) has seen a surge in its stock prices following a reported takeover bid of $17 a share from Thomas H. Lee. Maravai Lifesciences is a leading provider of biopharmaceutical services and technologies, offering a comprehensive suite of integrated solutions to accelerate the drug development process. Its capabilities span the entire lifecycle of biopharmaceutical development and manufacturing, from early research and development to commercial manufacture. Maravai’s products are used by pharmaceutical companies around the world to bring treatments to market quickly and efficiently.
Thomas H. Lee is a global private equity firm with extensive experience in the biopharmaceutical industry, so this deal could prove to be hugely beneficial for both parties involved. The proposed takeover is currently pending regulatory approval, so it remains to be seen how this story will develop.
Stock Price
As investors reacted to the news, MARAVAI LIFESCIENCES shares went up in price, demonstrating strong investor confidence in the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 717.73 | 153.28 | 21.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
| Operations | Investing | Financing |
| 458.75 | -95.76 | -166.19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.32k | 1.41k | 3.96 |
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 83.4% | 185.6% | 57.1% |
| FCF Margin | ROE | ROA |
| 60.8% | 48.0% | 11.1% |
Analysis
At GoodWhale, we recently conducted an analysis of MARAVAI LIFESCIENCES‘s wellbeing. Our Star Chart showed that MARAVAI LIFESCIENCES is strong in growth, medium in asset, profitability and weak in dividend. We classified MARAVAI LIFESCIENCES as “rhino”, a type of company that has achieved moderate revenue or earnings growth. For investors looking to invest in MARAVAI LIFESCIENCES, the company has a high health score of 8/10 with regard to its cashflows and debt. This indicates that it is capable of safely riding out any crisis without the risk of bankruptcy. Additionally, investors may be attracted to MARAVAI LIFESCIENCES for its impressive growth and asset management abilities. All in all, MARAVAI LIFESCIENCES is an interesting option for those looking to invest in a solid business. More…
Peers
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
Summary
Maravai LifeSciences saw an increase in stock price following reports of a potential $17 per share takeover bid from Thomas H. Lee Partners. Analysts note that the potential acquisition would be beneficial to both parties, as it could bolster Maravai’s presence in the life sciences market and allow for increased synergies with Thomas H. Lee’s portfolio companies. Investors have been bullish on the prospect of the deal, and the stock has continued to rise in trading. With more news expected to be released in the coming weeks, investors are closely monitoring the situation for further updates.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
